Increase hemoglobin level in severe malarial anemia while controlling parasitemia: A mathematical model

Area of Science:

• Immunology
• Parasitology
• Mathematical Biology

Background:

• Severe malarial anemia (SMA) is a major cause of malaria-related deaths.
• Macrophage migration inhibitory factor (MIF) and parasite-secreted MIF (PMIF) contribute to SMA by suppressing red blood cell (RBC) recruitment, leading to dangerously low hemoglobin (Hb).
• Artesunate, a first-line SMA treatment, reduces parasitemia but does not restore Hb levels, sometimes necessitating blood transfusions due to post-treatment hemolytic anemia.

Purpose of the Study:

• To investigate a combination therapy for SMA that simultaneously controls parasitemia and increases Hb levels.
• To explore the potential of Epoxyazadiradione (Epoxy), an experimental MIF inhibitor, in combination with artesunate for treating SMA.

Main Methods:

• Development and analysis of a mathematical model simulating SMA.
• Modeling the combined effects of artesunate and Epoxyazadiradione on parasite levels and Hb concentrations.

Main Results:

• Mathematical modeling indicates that combining artesunate with Epoxyazadiradione can effectively control parasitemia and increase Hb levels in SMA.
• Artesunate primarily reduces parasite load, while Epoxy primarily enhances Hb levels by inhibiting MIF.
• The two drugs demonstrate a complementary therapeutic action.

Conclusions:

• The combination of artesunate and Epoxyazadiradione presents a promising therapeutic strategy for SMA.
• Epoxy's MIF inhibitory action offers a potential mechanism to restore Hb levels, complementing artesunate's antimalarial effects.
• This combination therapy could potentially mitigate the need for blood transfusions in SMA patients.